Cargando…
Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters
Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRN...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159847/ https://www.ncbi.nlm.nih.gov/pubmed/37012419 http://dx.doi.org/10.1038/s41564-023-01352-8 |
| _version_ | 1785037181399597056 |
|---|---|
| author | Nouailles, Geraldine Adler, Julia M. Pennitz, Peter Peidli, Stefan Teixeira Alves, Luiz Gustavo Baumgardt, Morris Bushe, Judith Voss, Anne Langenhagen, Alina Langner, Christine Martin Vidal, Ricardo Pott, Fabian Kazmierski, Julia Ebenig, Aileen Lange, Mona V. Mühlebach, Michael D. Goekeri, Cengiz Simmons, Szandor Xing, Na Abdelgawad, Azza Herwig, Susanne Cichon, Günter Niemeyer, Daniela Drosten, Christian Goffinet, Christine Landthaler, Markus Blüthgen, Nils Wu, Haibo Witzenrath, Martin Gruber, Achim D. Praktiknjo, Samantha D. Osterrieder, Nikolaus Wyler, Emanuel Kunec, Dusan Trimpert, Jakob |
| author_facet | Nouailles, Geraldine Adler, Julia M. Pennitz, Peter Peidli, Stefan Teixeira Alves, Luiz Gustavo Baumgardt, Morris Bushe, Judith Voss, Anne Langenhagen, Alina Langner, Christine Martin Vidal, Ricardo Pott, Fabian Kazmierski, Julia Ebenig, Aileen Lange, Mona V. Mühlebach, Michael D. Goekeri, Cengiz Simmons, Szandor Xing, Na Abdelgawad, Azza Herwig, Susanne Cichon, Günter Niemeyer, Daniela Drosten, Christian Goffinet, Christine Landthaler, Markus Blüthgen, Nils Wu, Haibo Witzenrath, Martin Gruber, Achim D. Praktiknjo, Samantha D. Osterrieder, Nikolaus Wyler, Emanuel Kunec, Dusan Trimpert, Jakob |
| author_sort | Nouailles, Geraldine |
| collection | PubMed |
| description | Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2, the adenovirus-vectored spike vaccine Ad2-spike and the live-attenuated virus vaccine candidate sCPD9 in Syrian hamsters, using both homogeneous and heterologous vaccination regimens. Comparative vaccine efficacy was assessed by employing readouts from virus titrations to single-cell RNA sequencing. Our results show that sCPD9 vaccination elicited the most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation of pre-plasmablasts, strong systemic and mucosal humoral responses, and rapid recall of memory T cells from lung tissue after challenge with heterologous SARS-CoV-2. Overall, our results demonstrate that live-attenuated vaccines offer advantages over currently available COVID-19 vaccines. |
| format | Online Article Text |
| id | pubmed-10159847 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101598472023-05-06 Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters Nouailles, Geraldine Adler, Julia M. Pennitz, Peter Peidli, Stefan Teixeira Alves, Luiz Gustavo Baumgardt, Morris Bushe, Judith Voss, Anne Langenhagen, Alina Langner, Christine Martin Vidal, Ricardo Pott, Fabian Kazmierski, Julia Ebenig, Aileen Lange, Mona V. Mühlebach, Michael D. Goekeri, Cengiz Simmons, Szandor Xing, Na Abdelgawad, Azza Herwig, Susanne Cichon, Günter Niemeyer, Daniela Drosten, Christian Goffinet, Christine Landthaler, Markus Blüthgen, Nils Wu, Haibo Witzenrath, Martin Gruber, Achim D. Praktiknjo, Samantha D. Osterrieder, Nikolaus Wyler, Emanuel Kunec, Dusan Trimpert, Jakob Nat Microbiol Article Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2, the adenovirus-vectored spike vaccine Ad2-spike and the live-attenuated virus vaccine candidate sCPD9 in Syrian hamsters, using both homogeneous and heterologous vaccination regimens. Comparative vaccine efficacy was assessed by employing readouts from virus titrations to single-cell RNA sequencing. Our results show that sCPD9 vaccination elicited the most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation of pre-plasmablasts, strong systemic and mucosal humoral responses, and rapid recall of memory T cells from lung tissue after challenge with heterologous SARS-CoV-2. Overall, our results demonstrate that live-attenuated vaccines offer advantages over currently available COVID-19 vaccines. Nature Publishing Group UK 2023-04-03 2023 /pmc/articles/PMC10159847/ /pubmed/37012419 http://dx.doi.org/10.1038/s41564-023-01352-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Article Nouailles, Geraldine Adler, Julia M. Pennitz, Peter Peidli, Stefan Teixeira Alves, Luiz Gustavo Baumgardt, Morris Bushe, Judith Voss, Anne Langenhagen, Alina Langner, Christine Martin Vidal, Ricardo Pott, Fabian Kazmierski, Julia Ebenig, Aileen Lange, Mona V. Mühlebach, Michael D. Goekeri, Cengiz Simmons, Szandor Xing, Na Abdelgawad, Azza Herwig, Susanne Cichon, Günter Niemeyer, Daniela Drosten, Christian Goffinet, Christine Landthaler, Markus Blüthgen, Nils Wu, Haibo Witzenrath, Martin Gruber, Achim D. Praktiknjo, Samantha D. Osterrieder, Nikolaus Wyler, Emanuel Kunec, Dusan Trimpert, Jakob Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters |
| title | Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters |
| title_full | Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters |
| title_fullStr | Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters |
| title_full_unstemmed | Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters |
| title_short | Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters |
| title_sort | live-attenuated vaccine scpd9 elicits superior mucosal and systemic immunity to sars-cov-2 variants in hamsters |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159847/ https://www.ncbi.nlm.nih.gov/pubmed/37012419 http://dx.doi.org/10.1038/s41564-023-01352-8 |
| work_keys_str_mv | AT nouaillesgeraldine liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT adlerjuliam liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT pennitzpeter liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT peidlistefan liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT teixeiraalvesluizgustavo liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT baumgardtmorris liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT bushejudith liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT vossanne liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT langenhagenalina liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT langnerchristine liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT martinvidalricardo liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT pottfabian liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT kazmierskijulia liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT ebenigaileen liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT langemonav liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT muhlebachmichaeld liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT goekericengiz liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT simmonsszandor liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT xingna liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT abdelgawadazza liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT herwigsusanne liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT cichongunter liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT niemeyerdaniela liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT drostenchristian liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT goffinetchristine liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT landthalermarkus liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT bluthgennils liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT wuhaibo liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT witzenrathmartin liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT gruberachimd liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT praktiknjosamanthad liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT osterriedernikolaus liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT wyleremanuel liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT kunecdusan liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters AT trimpertjakob liveattenuatedvaccinescpd9elicitssuperiormucosalandsystemicimmunitytosarscov2variantsinhamsters |